Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-01-15

Clinical Trial Update: Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial of NBI-98854 in children and adolescents with Tourette syndrome completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NBI-98854

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Tourette Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-01-15